Physician profile
Sara Schmidt
NPI 1275066391
$8,041.64
in general payments reported to CMS, 2019-2025
51 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,664 · 2022: $1,459 · 2023: $1,706 · 2024: $1,447 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,919.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $922.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $795.11 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $746.40 | 2021-2025 | Jardiance |
| Abbvie INC. | $663.20 | 2021-2025 | |
| Lilly USA, LLC | $644.54 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $589.91 | 2021-2025 | Airsupra, Nexium, Fasenra |
| Amgen INC. | $352.68 | 2022-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $336.23 | 2021-2024 | Xarelto |
| Pfizer INC. | $325.09 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $275.17 | 2022-2024 | Eliquis |
| Astellas Pharma US INC | $171.56 | 2021-2024 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $167.74 | 2021-2022 | |
| Genzyme Corporation | $145.72 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $131.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $131.14 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.